BioWorld

July 27, 2009

View Archived Issues

Rigel Takes Hit on R788 Data, But Partnering Thesis Intact

Rigel Pharmaceuticals Inc. said a midstage study of rheumatoid arthritis drug R788 missed the mark, a development that might complicate partnership talks but won't end them. (BioWorld Today) Read More

VC Money: Biotech Finds a Cure for the Low-Cash Summer Blues

Read More

Vertex's Future Milestone Sale Creative If There's a Market

Read More

NewCo News: Intellikine Moves into Busy P13K Space with Tricks Up Its Sleeve

Read More

CytRx Bolsters Cash by $20M to Boost Lead Drug Programs

Read More

Not Satisfied with $80B, Will Obama Get More from PhRMA?

Read More

Other News To Note

Read More

Clinic Roundup

Read More